Trial Profile
A Single-blind, Randomized, Placebo-Controlled 3-Part Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled AZD0449 Following Single and Multiple Ascending Doses and to Investigate the Anti-Inflammatory Effect of Inhaled AZD0449
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 0449 (Primary) ; AZD 0449 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 29 Jun 2021 Status changed from recruiting to completed.
- 08 Apr 2021 Planned End Date changed from 31 May 2021 to 10 Jun 2021.
- 08 Apr 2021 Planned primary completion date changed from 31 May 2021 to 10 Jun 2021.